Document is current
Any future updates will be listed below
-
Authors
Wallvik, Niklas
Renlund, Henrik
Själander, Anders
-
Funding
Funding for this research was provided by:
Hjärt-Lungfonden (20150435)
Umea University
- License Information
-
More Information
Article History
Accepted: 21 October 2020
First Online: 2 November 2020
Compliance with ethical standards
:
: N.W and H.R declare that they have no conflict of interest. A.S was the principal investigator of the RE-VERSE AD study in Sweden and has received consultancy or lecture fees from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck Sharp and Dohme, Takeda Pharma and Pfizer.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University. Dnr 2015/145-31.
: Article was accepted for publication by all authors.
